WEDNESDAY, Aug. 5 (HealthDay News) -- Although many men with early stage testicular cancer are managed by surveillance, many do not receive the recommended follow-up testing, according to a study published online Aug. 3 in the Journal of Clinical Oncology.

Hua-yin Yu, M.D., from the University of California in Los Angeles, and colleagues analyzed data on compliance with recommended follow-up testing from 739 privately insured adult men with stage I testis cancer who underwent radical orchiectomy. Of these, 72 (9.7 percent) underwent retroperitoneal lymph node dissection, 388 (52.5 percent) underwent radiation therapy, and 279 (37.8 percent) were managed with surveillance.

The researchers found that compliance with post-adjuvant follow-up testing was poor in the surveillance group and worsened with increasing time after diagnosis, with almost 30 percent of patients receiving no abdominal imaging, chest imaging, or tumor marker tests in the first year. Patients who underwent retroperitoneal lymph node dissection were most compliant in the first year. In spite of the poor compliance, recurrence rates were similar to those previously reported in the literature, according to the study.

"Surveillance is a widely accepted strategy in clinical stage I testicular cancer treatment in the community," Yu and colleagues conclude. "However, follow-up care recommendations developed at referral centers are not being adhered to in the community."

Abstract
Full Text (subscription or payment may be required)